ASX：AT1上市公司Atomo Diagnostics近日宣布，已从澳大利亚国家HIV协会(NAPWHA)获得价值约63万澳元的HIV自检测试盒订单，该订单被公司视为重要收入来源。 这笔订单将支持由联邦政府资助的全国免费HIV自检项目的持续运行。
数据显示，该项目在提高关键高风险人群检测率方面取得了显著成功，特别是针对那些此前检测不足或从未进行过检测的人群。 据了解，该项目得到了全球最大LGBTIQ+社群社交网络应用Grindr的支持，项目扩张确保了更多HIV自检测试盒的可用性，并提高了人们对免费居家检测的认识。
Atomo Diagnostics首席执行官John Kelly表示：「我们与NAPWHA及澳大利亚其他合作伙伴建立了良好的工作关系，确保那些希望了解自身状况的人能够获得 discreet、便捷的检测服务。我们很高兴能为这一宝贵项目提供更多Atomo测试产品。」 作为一家总部位于澳大利亚的医疗器械公司，Atomo专注于向全球诊断市场供应独特的集成快速诊断测试(Rapid Diagnostic Test, RDT)设备。公司专利设备简化了测试流程，提高了在即时检测(Point-of-Care, POC)和居家检测应用中的可用性和可靠性。Atomo已在多个国际市场商业化其产品，并在性健康和女性健康等传染病检测应用领域建立了供应协议。
资料来源：ASX 官方公告（摘要与分析均为本网站原创内容）。
完整公告请以 ASX 官方网站为准。
免责声明：本内容不构成投资建议，版权归原公告发布方所有。
Source: This content is based on official announcements released by the ASX. It does not constitute a full reproduction, translation, or redistribution of the original announcement. For complete and official information, please refer to the original announcement published on the ASX website.
Copyright Notice: The copyright of ASX company announcements belongs to the ASX or the respective listed companies. This website provides summaries, interpretations, and analytical content derived from publicly available information. It does not copy, store, distribute, or host the original announcement content. For the full announcement, please visit the official ASX website.
Disclaimer: The information provided herein is for general informational purposes only and does not constitute financial, legal, or investment advice. No warranty is given regarding the accuracy, completeness, or timeliness of the content. Please consult a licensed financial adviser before making any investment decisions. All investments carry risks.